title: [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].
abstract: Osteoporosis has become a global public health issue due to the fact that the world population has gotten older. In the past ten years we have witnessed a great improvement in the treatment of postmenopausal osteoporosis. The anti-resorptive drugs are the most presribed ones. In the last couple of years osteoanabolic drug, a teriparatid, was introduced into the clinical use, and recently a strontium ranelate has occured as a drug with osteoanabolic and antiresorptive effect in bone formation. Clinical trials (phase III) have proved the efficiency of strontium ranelate in postmenopausal osteoporosis treatment. Strontium ranelate is a drug characterized by the new paradigm of action mechanism on bone, which has its place among the already well-proven drugs in postmenopausal osteoporosis treatment.
authors.affiliation: Zavod za endokrinologiju, Klinika za unutrasnje bolesti, KBC Zagreb.
authors.forename: Mirko
authors.initials: M
authors.lastname: Korsić
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Giljević
authors.forename: Darko
authors.initials: D
authors.lastname: Kastelan
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate